Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

Core Insights - Femasys Inc. has published positive data from initial clinical trials of FemBloc, a non-surgical permanent birth control method, demonstrating compelling effectiveness and five-year safety [1][3][4] - The pregnancy rate for FemBloc subjects was reported at 0%, significantly lower than the historical control goal of 6% for surgical sterilization [3] - The company aims to provide a safer, more accessible in-office alternative to traditional surgical sterilization, with high satisfaction reported from both patients and practitioners [2][4] Company Overview - Femasys is a biomedical innovator focused on women's health, developing a portfolio of minimally invasive therapeutic and diagnostic solutions [5] - The company’s products, including FemBloc, have received global regulatory approvals and are being commercialized in the U.S. and select countries [5] - FemBloc is positioned as a revolutionary non-surgical method for permanent contraception, utilizing a proprietary synthetic tissue adhesive to occlude the fallopian tubes [4][5] Clinical Trial Data - The publication titled "FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes" includes data from three clinical trials, confirming the effectiveness and safety of FemBloc [3][6] - No serious adverse events were reported among the 229 subjects, and the safety profile aligns with typical intrauterine transcervical procedures [3] - The pivotal clinical trial for U.S. approval (NCT05977751) is currently enrolling participants [4][5]